ImmuCell (ICCC) Stock Price, News & Analysis

Company Overview

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases. Through proprietary manufacturing processes, ImmuCell delivers bioactive immunoglobulins and immune-supporting factors to strengthen the health and survivability of young ruminants.

In addition to its passive immunology franchise, ImmuCell provides veterinary diagnostic assays and treatment products targeting common cattle diseases. Its in-house laboratory services encompass immunodiagnostic tests and therapeutic interventions aimed at improving udder health and controlling infectious conditions within herds across North America.

Since its founding, ImmuCell has cultivated partnerships with animal health professionals, distributors, and research organizations to expand its reach throughout the United States and into select international markets. The company is led by a management team with expertise in veterinary science, agriculture, and commercial operations, positioning it to advance innovative solutions for livestock producers worldwide.

Key Stats

• Today's Range: $9.29 to $9.58
• 50-Day Range: $6.38 to $10.63
• 52-Week Range: $4.52 to $10.75
• Volume: 34,226 shs
• Average Volume: 22,765 shs
• Market Capitalization: $85.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

ImmuCell Stock Analysis - MarketRank™

ImmuCell scored higher than 10% of companies evaluated by MarketBeat, and ranked 813th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

ImmuCell has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

ImmuCell has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmuCell is -158.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmuCell is -158.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ImmuCell has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.11% of the float of ImmuCell has been sold short.

Short Interest Ratio / Days to Cover

ImmuCell has a short interest ratio ("days to cover") of 0.21, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmuCell has recently decreased by 12.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmuCell does not currently pay a dividend.

Dividend Growth

ImmuCell does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmuCell insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.70% of the stock of ImmuCell is held by insiders.

Percentage Held by Institutions

13.47% of the stock of ImmuCell is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/18/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ICCC
• CIK: 811641
• Web: www.immucell.com
• Phone: (207) 878-2770
• Fax: 207-878-2117
• Employees: 70
• Year Founded: 1982

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.04 million
• Net Margins: -1.82%
• Pretax Margin: -1.75%
• Return on Equity: -1.88%
• Return on Assets: -1.22%

Debt

• Debt-to-Equity Ratio: 0.24
• Current Ratio: 4.82
• Quick Ratio: 2.60

Sales & Book Value

• Annual Sales: $27.64 million
• Price / Sales: 3.11
• Cash Flow: $0.19 per share
• Price / Cash Flow: 48.68
• Book Value: $2.99 per share
• Price / Book: 3.17

Miscellaneous

• Outstanding Shares: 9,050,000
• Free Float: 8,531,000
• Market Cap: $85.88 million
• Optionable: Not Optionable
• Beta: 0.55